![Robert Lisicki](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: - $ in data 31/08/2026
Robert Lisicki is Chief Commercial Officer & Executive VP at Arcutis Biotherapeutics, Inc. since 2026.
Formerly, Mr. Lisicki was Chief Executive Officer & Director at Zura Bio Ltd. from 2024 to 2025, Independent Director at Cadrenal Therapeutics, Inc. from 2023 to 2025, Director at Adiso Therapeutics, Inc. from 2023 to 2024, Chief Executive Officer & Director at InCarda Therapeutics, Inc. from 2022 to 2023, Chief Commercial Officer & Executive VP at Arena Pharmaceuticals, Inc. from 2018 to 2022, Chief Customer Officer, SVP-Sales & Marketing at Daiichi Sankyo, Inc. from 2014 to 2018, Vice President & General Manager at Amgen, Inc. from 2005 to 2014, and General Manager & Vice President-Cardio Metabolic at Regeneron Pharmaceuticals, Inc. Education includes undergraduate studies at State University of New York at Albany.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 20/04/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ARCUTIS BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 17/08/2026 |
| Società | Posizione | Fine |
|---|---|---|
| ZURA BIO LIMITED | Amministratore Delegato | 10/10/2025 |
| CADRENAL THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 15/07/2025 |
Adiso Therapeutics, Inc.
 Adiso Therapeutics, Inc. BiotechnologyHealth Technology Provides biotechnology research services | Direttore/Membro del Consiglio | 01/08/2024 |
InCarda Therapeutics, Inc.
 InCarda Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biopharmaceutical company that develops and manufactures innovative therapies for atrial fibrillation & cardiac rhythm disorders | Amministratore Delegato | 01/03/2023 |
| ARENA PHARMACEUTICALS | Corporate Officer/Principal | 01/03/2022 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 10 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Regeneron Pharmaceuticals, Inc.
 Regeneron Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures and commercializes medicines for diseases | Health Technology |
Arena Pharmaceuticals, Inc.
 Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products | Health Technology |
State University of New York at Albany
 State University of New York at Albany Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Daiichi Sankyo, Inc.
 Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceutical products | Health Technology |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biopharmaceutical company that develops and manufactures innovative therapies for atrial fibrillation & cardiac rhythm disorders | Commercial Services |
Arcutis Biotherapeutics, Inc.
 Arcutis Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an immunodermatology drug development company | Health Technology |
Adiso Therapeutics, Inc.
Adiso Therapeutics, Inc. BiotechnologyHealth Technology Provides biotechnology research services | Health Technology |
Zura Bio Ltd.
 Zura Bio Ltd. BiotechnologyHealth Technology Operates as a multi-asset clinical-stage biotechnology company that focuses on develops novel medicines for immune and inflammatory disorders | Health Technology |
Cadrenal Therapeutics, Inc.
 Cadrenal Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel therapy with orphan drug indication | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
